Huahui Health and BeiGene Enter Global Exclusive Option, License, and Collaboration Agreement for Novel Trispecific Antibody HH160 in Oncology

Huahui Health Announces Global Exclusive Option, License and Collaboration Agreement with BeOne Medicines for Novel Oncology Immuno-Oncology Trispecific Antibody HH160, Granting BeOne Medicines an Exclusive Option for the Development, Manufacturing, and Commercialization of the Product.

Under the agreement, BeiGene will pay Huahui Health an upfront payment of $20 million. If BeiGene exercises its option, Huahui Health will be entitled to receive an additional option exercise payment of $100 million. Upon the achievement of development and regulatory milestones, Huahui Health will be eligible for milestone payments of up to $374 million. Upon the achievement of sales milestones, Huahui Health will be eligible for milestone payments of up to $1.53 billion, as well as tiered royalties. Furthermore, both parties will actively engage in discussions regarding BeiGene’s potential participation in Huahui Health’s financing activities, with specific transaction terms and details to be negotiated separately.

Dr. Chen Bin, CEO of Huahui Health, stated, “Huahui Health has established a comprehensive R&D engine covering the entire drug development process, enabling the independent identification of novel targets and the development of proprietary candidate drugs. Our product pipeline includes one marketed drug and multiple novel therapeutics in Phase II clinical trials, with our R&D capabilities widely recognized within the industry. BeiGene possesses outstanding innovation capabilities and global development advantages. We are delighted to engage in deep collaboration with BeiGene to jointly advance the development of HH160, a novel tumor immunotherapy trispecific antibody, aiming to bring innovative cancer immunotherapies to patients worldwide at the earliest possible date.”

HH160 is a novel trispecific antibody developed by Huahui Health using its proprietary PolyBoost™ multispecific antibody platform. HH160 simultaneously targets three clinically validated tumor immunity and anti-angiogenesis targets: PD-1, CTLA-4, and VEGF-A. The synergistic “three-in-one” mechanism of this drug is expected to enhance efficacy, achieve tumor-specific drug distribution, and reduce treatment-related side effects. The positive preclinical results of HH160 were presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting held in Chicago, USA.

Huahui Health, established in Beijing in 2015, leverages its profound scientific research expertise to focus on viral hepatitis, liver diseases, and oncology. With a patient-centric approach, the company is dedicated to developing first-in-class and best-in-class breakthrough therapies. Upholding the principles of “innovation, pragmatism, collaboration, and mutual benefit,” Huahui Health has built a world-class platform covering the entire new drug development process, creating a powerful engine for the continuous generation of breakthrough therapies, and is committed to benefiting patients worldwide through innovative treatments.

BeiGene is a global oncology innovation company dedicated to developing innovative anti-cancer therapies for cancer patients worldwide. The company boasts a robust portfolio in hematology and solid tumors, and continuously accelerates the development of a diverse and innovative drug pipeline through strong in-house R&D capabilities and strategic external collaborations. Currently, BeiGene has a growing team across six continents, committed to enhancing the accessibility of innovative medicines and benefiting more patients globally, driven by scientific excellence and efficient execution.